A carregar...
An evidence-based review of certolizumab pegol in the treatment of active psoriatic arthritis: place in therapy
Certolizumab pegol (CZP) is a pegylated humanized tumor necrosis factor-α inhibitor (TNFi) approved for the treatment of psoriatic arthritis (PsA) in Europe, the USA, and Latin American countries. CZP neutralizes TNF-α at its soluble and membrane portions. Due to the lack of Fc region, it does not i...
Na minha lista:
| Publicado no: | Open Access Rheumatol |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Dove Medical Press
2016
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5098767/ https://ncbi.nlm.nih.gov/pubmed/27843368 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OARRR.S56837 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|